Navigation Links
Questcor Pharmaceuticals Responds to Questions From Investor Blog
Date:1/16/2012

In the current situation, the Company is concerned about the apparent tactics of StreetSweeper and its background, and believes that responding to its questions and publicly disclosing the content of the questions and answers is in the best interest of the Company's shareholders. The questions asked by StreetSweeper that it provided on January 9th and Questcor's responses to those questions are set forth below.  Many of the questions are vague, imprecise, are based upon erroneous assumptions or incomplete information.  Notwithstanding, the Company provided responses based upon a reasonable interpretation of the questions.  Certain responses are limited because of the manner in which the questions were phrased.  The Company, under no circumstances, adopts, endorses or validates any factual statements or assumptions posed by any question.

Prior to Questcor providing responses to the questions provided by StreetSweeper on January 9th, Ms. Davis asked the Company to discuss its compliance program.  Questcor noted that it would do so later in the call and provided a response to her. That response is provided at the end of this press release.  The questions provided on January 9th and Questcor's responses to the questions are set forth below:

1.  Is Acthar considered a first-line or a second-line treatment for MS flares? Either way, please explain.

Questcor Response: As stated in its FDA approved label, H.P. Acthar® Gel is approved for the "Treatment of acute exacerbations of multiple sclerosis in adults." Exacerbations are also commonly referred to as flares or relapses. The indication, as approved by FDA, is not limited to a specific line of therapy.  IV corticosterioids are widely considered first-line therapy for acute exacerbations of MS. It is solely up to the prescribing physician to decide when Acthar should be prescribed for any particular patient. We do not always know whether the doctor
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Questcor Pharmaceuticals Issues Statement
2. Questcor Pharmaceuticals Reports Strong Finish to 2011
3. Questcor Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference on November 30, 2011
4. Questcor Pharmaceuticals to Present at CLSAs 4th Annual AsiaUSA Forum on November 7, 2011
5. Questcor and Child Neurology Foundation Support the 3rd Annual Infantile Spasms (IS) Awareness Week
6. Questcor Reports Third Quarter Financial Results
7. Questcor to Report Third Quarter 2011 Earnings and Conduct Conference Call on October 25, 2011
8. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011
9. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
10. Questcor Provides Updated New Paid Prescription Trends
11. UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Resources Group finds that the market for colorectal cancer (CRC) ... in the United States , ... Italy , Spain , the ... . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin and Bristol-Myers Squibb/Eli ... of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, Alchemia,s HA-irinotecan and ...
(Date:8/28/2014)... YORK , Aug. 28, 2014 Levi ... been commenced in the United States District Court for ... behalf of investors who purchased Galectin Therapeutics Inc. ("Galectin" ... 2014 and July 28, 2014. For more ... complaint alleges that during the Class Period the Company ...
(Date:8/28/2014)... , Aug. 28, 2014 Nonin Medical, ... leader in noninvasive medical monitoring, today announced that the ... Model 3231 OEM/eHealth finger pulse oximeter for use in ... pulse oximeter plugs into a telemedicine hub or kiosk ... pulse rate in pediatric to adult patients. The Model ...
Breaking Medicine Technology:The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... and Company (NYSE: LLY ) today issued ... and chief executive officer about his meeting today with ... job creation, American innovation and competiveness: "It,s ... and take part in this very important dialogue today ...
... Dec. 15, 2010 Johnson & Johnson (NYSE: ... Worldwide Chairman, Medical Devices & Diagnostics (MD&D) and Sheri ... Chairmen of the Executive Committee and join William C. ... in an expanded Office of the Chairman.  Both appointments ...
Cached Medicine Technology:Lilly Statement Regarding President Obama's Meeting With U.S. Business Leaders 2Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 2Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 3
(Date:8/29/2014)... Auckland, NZ (PRWEB) August 29, 2014 ... of Greg Allen to Chief Executive Officer effective from ... Chief Technology Officer for Winscribe. , “During this time ... Winscribe than Greg Allen,” said Matthew Weavers, Winscribe’s Founder ... leader with a wealth of commercial, IT and management ...
(Date:8/28/2014)... 2014 Career Step, an online provider ... new video designed to help students and career seekers ... billing field. The video details what medical coders and ... professionals, and the education requirements for entering this field. ... often overlooked when people are considering a career in ...
(Date:8/28/2014)... FL (PRWEB) August 29, 2014 ... that brings pharmaceutical industry precision to the development ... zoning approval for its primary location in Sarasota ... and decisively with a total commitment to attracting ... forward to creating," says David Wright, President and ...
(Date:8/28/2014)... When David Gergen, President of ... Mark Brnovich, was asked to publicly support Mr. Brnovich ... Attorney General seat in the State of Arizona, Mr. ... of Cardinal Hall of Fame wide receiver Roy Green ... Mark Walczak. Green, Kennard and Walczak are members of ...
(Date:8/28/2014)... Farmington, New York (PRWEB) August 29, 2014 ... Autumn as they will be traveling around the country ... with a final show in November. The New Energy ... exhibit sharing their timber frame design and build expertise, ... addition, Drake Ambrosino , New Energy Works’ Mid-West ...
Breaking Medicine News(10 mins):Health News:Winscribe Names Greg Allen as CEO 2Health News:Career Step Releases New Video Designed to Help Students Explore the Medical Coding and Billing Field 2Health News:Sarasota County Approves Zoning for Leading Medical Cannabis Firm AltMed 2Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 2Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 3
... between tests, researchers say , THURSDAY, Oct. 4 (HealthDay ... DNA testing enables earlier detection of lesions that lead ... women could go longer between screenings, say researchers at ... study included more than 17,000 women ages 29 to ...
... Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced ... to retire next year.,Renton, 60, will remain chairman of ... the company is initiating a search for a successor. ... to the newly created,position of executive vice president & ...
... Inc.,(Nasdaq: ANSV ) today announced that it ... review the company,s launch and commercialization,plans for Zingo(TM) ... will take place on Friday,October 12, 2007 from ... York City. To,access the live audio broadcast or ...
... the,November 2006 Rand Corp. study, health care provided ... a year nationally and that 68,percent of illegal ... of millions of newcomers, U.S.-born and foreign-born relatives ... to the U.S. population.,They will also consume energy, ...
... ANA, Calif., Oct. 4 More than 35,million children ... the streets in,costume this Halloween. Although hours of planning ... people fail to consider,the importance of security. "Today, most ... in a sealed wrapper and safe to eat," says ...
... ... organizations, ST. PAUL, Minn., Oct. ... announced today it has,achieved URAC Pharmacy Benefit Management (PBM) accreditation. ... practices, promote quality improvement and protect and,empower consumers. Prime began its ...
Cached Medicine News:Health News:Gene-Based Screen Spots Cervical Cancer Earlier 2Health News:Onyx Pharmaceuticals Announces Management Changes 2Health News:Onyx Pharmaceuticals Announces Management Changes 3Health News:Anesiva to Unveil Zingo(TM) Commercialization Plans 2Health News:Message for Activists at Latino National Congreso Convention: Amnesty Will Exacerbate National Problems and Turn the U.S. into Another Mexico 2Health News:Safety Tips for a Fun and Spooky Halloween 2Health News:Prime Therapeutics Announces URAC Accreditation 2
Colorimetric Assay of Antithrombin III Activity by STA© Analyzers. Bovine thrombin ~12NIH units/mL, freeze-dried....
Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
Colorimetric Assay of Unfractionated and Low Molecular Weight Heparins by STA© Analyzers. Lyophilized, patent-pending chromogenic substate, CBS 52.44 of ~4.2 moles/vial and bovine factor Xa ~1.1...
Substrate Plasma for Factor VII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VII has been removed by selective immuno-adsorption....
Medicine Products: